Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffery Schoonover

Phlebology Carmel, IN Medical Doctor

NPI 1245205293 CMS profile 11065

11590 N Meridian St Ste 270, Carmel, IN 46032

Open in the dashboard

General payments

$48,294

124 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeffery Schoonover of Carmel, IN is reported in the CMS Open Payments database as having received $48,294 across 124 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Phlebology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,026 19
2024 General $10,890 15
2023 General $3,154 21
2022 General $3,936 23
2021 General $2,408 20
2020 General $10,044 14
2019 General $11,838 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffery Schoonover
  • Phlebology median
  • Middle half of Phlebology
  • National median

In program year 2025, general payments to Jeffery Schoonover were reported at $6,026. Among 79 Phlebology profiles paid that year, the median was $146 and the middle half received between $41 and $404.

Show as a table
Year Jeffery Schoonover Phlebology median Middle half National median
2019 $11,838 $184 $47–$602 $163
2020 $10,044 $129 $64–$375 $114
2021 $2,408 $144 $48–$585 $132
2022 $3,936 $171 $46–$575 $149
2023 $3,154 $207 $37–$633 $160
2024 $10,890 $175 $53–$445 $164
2025 $6,026 $146 $41–$404 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AngioDynamics, Inc. $32,569 17 payments
  2. Tactile Systems Technology Inc $13,194 36 payments
  3. Bard Peripheral Vascular, Inc. $1,096 35 payments
  4. Boston Scientific Corporation $699 15 payments
  5. Medtronic, Inc. $187 5 payments
  6. Medtronic Vascular, Inc. $135 1 payment
  7. Abbott Laboratories $83 1 payment
  8. Pfizer Inc. $82 4 payments
  9. Venclose Inc. $68 2 payments
  10. Merz North America, Inc. $62 1 payment
  11. Other $120 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $21,275 7 payments
  2. Long term medical supply or device loan $9,600 8 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $9,213 4 payments
  4. Food and Beverage $4,476 101 payments
  5. Travel and Lodging $2,831 3 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $900 1 payment
Products named General payments · program years 2019–2025
  1. EVLT $19,200 4 payments
  2. Flexitouch Plus $12,781 25 payments
  3. VenaCure 1470 Pro Et $9,120 8 payments
  4. Entre Plus $8,234 9 payments
  5. Nimbl $3,417 11 payments
  6. VenaCure 1470 Pro Id $2,400 2 payments
  7. entre Pneumatic Compressor $1,130 5 payments
  8. Venclose Maven Catheter $688 17 payments
  9. ENTRE Pneumatic Compressor $413 11 payments
  10. ACTITOUCH $413 11 payments
  11. Other $2,165 63 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

24

Median for Family Practice: 1,826

Drug cost

$15,321

Median for Family Practice: $120,094

Branded share of claims

100%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 24 $15,321

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$211,232

Medicare's payments for the services billed

Medicare patients

353

Average age 74

Services billed

2,046

270 women, 83 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 58%
Arthritis 51%
Depression 20%
Osteoporosis 20%
Diabetes 18%
Ischemic heart disease 14%
Cancer 14%
Chronic kidney disease 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

124 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record